Collegium Pharmaceutical Inc (COLL) was Initiated by Gabelli & Co to “Buy” and the brokerage firm has set the Price Target at $25. Gabelli & Co advised their investors in a research report released on Sep 13, 2016.
Collegium Pharmaceutical Inc closed down -0.39 points or -4.18% at $8.94 with 197,778 shares getting traded on Monday. Post opening the session at $9.24, the shares hit an intraday low of $8.791 and an intraday high of $9.48 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Aug 15, 2016, John A. Fallon (director) purchased 2,375 shares at $10.59 per share price.
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate Xtampza ER (Xtampza) is an abuse-deterrent extended-release oral formulation of oxycodone opioid medication. Xtampza has the same active ingredient as OxyContin OP which is the abuse-deterrent extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing crushing and/or dissolving Xtampza and then taking it orally or smoking snorting or injecting it did not change its drug release profile.